| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/24/2003 | US20030078252 Used to treat abnormal cell growth and central nervous system disorders |
| 04/24/2003 | US20030078239 Ketone compounds and compositions for cholesterol management and related uses |
| 04/24/2003 | US20030078234 Applying semi-crystalline acetylglucosamine polysaccharide for treating vasoconstriction, reduction in blood flow |
| 04/24/2003 | US20030078232 A stimulants for bone marrow cell proliferation, countering the toxic side effect of drugs, in particular chemotherapeutic drugs, such as leukopenia and neutropenia |
| 04/24/2003 | US20030078212 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 04/24/2003 | US20030077802 Human PRL1 phosphatase |
| 04/24/2003 | US20030077756 Identification and modification of immunodominant epitopes in polypeptides |
| 04/24/2003 | US20030077753 Diglycosylated erythropoietin |
| 04/24/2003 | US20030077752 Factor VIII glycoforms |
| 04/24/2003 | US20030077734 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 04/24/2003 | US20030077682 Arginine free composition for use in treatment of thrombsis |
| 04/24/2003 | US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 04/24/2003 | US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli |
| 04/24/2003 | US20030077280 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated T cells and thereby inhibits T cell activation of B cells |
| 04/24/2003 | US20030077279 Methods for treating vascular disease by inhibiting toll-like receptor-4 |
| 04/24/2003 | US20030077243 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/24/2003 | CA2727642A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2463925A1 Bone anti-resorptive compounds |
| 04/24/2003 | CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | CA2463628A1 Himbacine analogues as thrombin receptor antagonists |
| 04/24/2003 | CA2463518A1 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | CA2463426A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof |
| 04/24/2003 | CA2462147A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/24/2003 | CA2461836A1 Detection and treatment of intravascular lesions |
| 04/24/2003 | CA2460685A1 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 04/24/2003 | CA2458981A1 Combinations comprising cox-2 inhibitors and aspirin |
| 04/23/2003 | EP1304379A2 Humanised antibody against CD18 |
| 04/23/2003 | EP1304113A1 Isolated stromal cells and methods of using the same |
| 04/23/2003 | EP1304112A1 Isolated stromal cells and methods of using the same |
| 04/23/2003 | EP1304101A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| 04/23/2003 | EP1303592A1 Novel protein derived from agkistrodon saxatilis emelianov and process for preparing the same |
| 04/23/2003 | EP1303513A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| 04/23/2003 | EP1303510A2 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 04/23/2003 | EP1303507A1 Pyrimidine derivatives |
| 04/23/2003 | EP1303499A1 Tetrazole derivatives |
| 04/23/2003 | EP1303491A1 Thrombin inhibitors comprising an aminoisoquinoline group |
| 04/23/2003 | EP1303482A2 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 04/23/2003 | EP1303310A1 USE OF THE INTERFERON RECEPTOR 2c POLYPEPTIDE CHAIN TO ENHANCE THE ANTI-GROWTH EFFECTS OF TYPE I INTERFERONS |
| 04/23/2003 | EP1303305A2 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 04/23/2003 | EP1303296A1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 04/23/2003 | EP1303292A1 Chemokine conjugates |
| 04/23/2003 | EP1303286A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 04/23/2003 | EP1303264A1 Compositions and methods for treating cardiovascular disorders |
| 04/23/2003 | EP1303262A2 Use of a spla2 inhibitor for the treatment of sepsis |
| 04/23/2003 | EP1303259A1 Prolonged release microspheres for injection delivery and preparation method |
| 04/23/2003 | EP1063230B1 Cyclic amino compounds |
| 04/23/2003 | EP1054913B1 Method for the production of polymers from n-vinyl compounds |
| 04/23/2003 | EP0863762A4 Methods of production and use of liquid formulations of plasma proteins |
| 04/23/2003 | EP0836615B1 New thrombin inhibitors, their preparation and use |
| 04/23/2003 | EP0672145B1 Interleukin-3 (il-3) multiple mutation polypeptides |
| 04/23/2003 | CN1413241A Dry compositions containing hydrophobic amino acid |
| 04/23/2003 | CN1413211A Substituted 1,3,4-oxadiazoles and method of producing TNF-alpha levels |
| 04/23/2003 | CN1413207A 5-membered ring heterocyclic compounds with nitrogen |
| 04/23/2003 | CN1413189A Benzamidine derivatives |
| 04/23/2003 | CN1413107A Use of hypoglycemic agent for treating impaired clucose metabolism |
| 04/23/2003 | CN1413105A Novel method of treatment |
| 04/23/2003 | CN1411816A New anticoagulant medicine |
| 04/23/2003 | CN1411811A 血液循环改善剂 Blood circulation improving agent |
| 04/23/2003 | CN1411809A Usage and composition of pyridine onium derivative for curing application |
| 04/23/2003 | CN1411800A Cosmetic composition and method |
| 04/23/2003 | CN1106384C Indoline-2-one derivatives, its preparing method and its medicinal compositions |
| 04/23/2003 | CN1106270C Multi-action particle for structuring biological media |
| 04/22/2003 | US6552062 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity |
| 04/22/2003 | US6552042 Anticoagulants |
| 04/22/2003 | US6552038 Anticoagulant agents |
| 04/22/2003 | US6552030 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine |
| 04/22/2003 | US6552029 For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis |
| 04/22/2003 | US6552019 Inhibitors of p38 |
| 04/22/2003 | US6552015 Azabicycloalkane derivatives and therapeutic uses thereof |
| 04/22/2003 | US6552008 Administering effective amount of a selected azo-pyrazole derivative for therapy of thrombocytopenia |
| 04/22/2003 | CA2308780C Novel derivatives of 2,3-methanoamino acids, process for their preparation and pharmaceutical compositions containing them |
| 04/22/2003 | CA2287054C 1,3,8-triazaspiro¬4,5|decanone compounds as orl1-receptor agonists |
| 04/22/2003 | CA2253869C Substituted oxobutyric acids as matrix metalloprotease inhibitors |
| 04/17/2003 | WO2003031939A2 Protein modification and maintenance molecules |
| 04/17/2003 | WO2003031598A2 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use |
| 04/17/2003 | WO2003031589A2 Peptides and related compounds having thrombopoietic activity |
| 04/17/2003 | WO2003031476A1 Antibody of human origin for inhibiting thrombocytes aggregation |
| 04/17/2003 | WO2003031468A1 Therapeutic and diagnostic molecules that are capable of interacting with socs proteins |
| 04/17/2003 | WO2003031464A2 Remodeling and glycoconjugation of peptides |
| 04/17/2003 | WO2003031447A2 Pyrimidine derivatives |
| 04/17/2003 | WO2003031440A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 04/17/2003 | WO2003031418A1 3,4-dihydro-1h-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/17/2003 | WO2003031410A1 Ligands of melanocortin receptors and compositions and methods related thereto |
| 04/17/2003 | WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS |
| 04/17/2003 | WO2003030993A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 04/17/2003 | WO2003030944A2 Inhibition of stat-1 |
| 04/17/2003 | WO2003030942A1 Pharmaceutical formulation |
| 04/17/2003 | WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | WO2003030897A1 Pyrrolidinone derivatives |
| 04/17/2003 | WO2003030878A2 Galenic microparticulate oral formulation |
| 04/17/2003 | WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 04/17/2003 | WO2003030827A2 Compositions for and methods of treating and preventing sirs/sepsis |
| 04/17/2003 | WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor |
| 04/17/2003 | WO2003005999A3 Methods of treating cytokine mediated diseases |
| 04/17/2003 | WO2002070706A3 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 04/17/2003 | WO2002032445A3 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/17/2003 | WO2002029036A3 Lipid metabolism enzymes |
| 04/17/2003 | WO2002024891A3 B7-like molecules and uses thereof |
| 04/17/2003 | WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 04/17/2003 | WO2001078709A3 Treatment of neurodegenerative disease |